FAQ

Raloxifene

Known as: RAL, RALOX, LY 139481 
The active ingredient in a drug used to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of the disease or who… (More)

Topic mentions per year

Topic mentions per year

1978-2017
010203019782017

Related topics

Related topics

11 relations
Drug AllergyOsteoporosis, PostmenopausalPregnancyRaloxifene Hydrochloride
(More)

Broader (3)

Estrogen AntagonistsEstrogens, SyntheticSelective Estrogen Receptor Modulators

Narrower (2)

EvistaLY-139481

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Raloxifene
Drug Allergy
Pregnancy
Thromboembolism
Osteoporosis, Postmenopausal
Estrogen Antagonists

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
BACKGROUND Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2012
2012
Detection of sentinel lymph nodes in patients with endometrial cancer undergoing robotic-assisted staging: a comparison of colorimetric and fluorescence imaging.
OBJECTIVE To retrospectively compare results from lymphatic mapping of pelvic sentinel lymph nodes (SLN) using fluorescence near… (More)
Is this relevant?
2012
2012
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.
BACKGROUND : Switching from boosted protease inhibitors (PI/r) to raltegravir (RAL) results in a better plasma lipid profile than… (More)
Is this relevant?
2009
2009
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
OBJECTIVE : Evaluate HIV-1 subtype B integrase gene evolution in patients failing raltegravir (RAL)-based savage regimens by… (More)
Is this relevant?
2007
2007
Electroreception and Communication in Fishes
To the memory of Thomas Szabo eminent pioneer in the field of electroreception gentleman und friend Abbreviations Abbreviations… (More)
Is this relevant?
2006
2006
Raloxifene enhances vertebral mechanical properties independent of bone density.
Anti-remodeling agents produce similar reductions in vertebral fracture risk despite large differences in BMD changes suggesting… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells.
Selective estrogen receptor modulators (SERMs) such as tamoxifen are effective in the treatment of many estrogen receptor… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats.
Obesity, from declining estrogen levels after menopause, increases the risk of heart disease, diabetes, and hypertension… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1989
1989
Suppression of spontaneous LH surges in estrogen-treated ovariectomized rats by microimplants of antiestrogens into the preoptic brain.
Studies by others have shown that parenteral administration of antiestrogens blocks the positive feedback effect of estrogen on… (More)
Is this relevant?
1984
1984
Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells.
The non-steroidal antioestrogens tamoxifen, 4-hydroxytamoxifen, trioxifene, LY 117018 and LY 139481 have widely divergent… (More)
Is this relevant?